Actinogen Medical Ltd
ACW
Company Profile
Business description
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Contact
109 Pitt Street
Level 9, Suite 901
SydneyNSW2000
AUST: +61 289647401
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
Our view after latest earnings report.
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.20 | 75.80 | -0.83% |
| CAC 40 | 8,062.04 | 47.75 | -0.59% |
| DAX 40 | 23,945.66 | 186.75 | -0.77% |
| Dow JONES (US) | 47,252.79 | 83.89 | -0.18% |
| FTSE 100 | 9,701.70 | 0.33 | 0.00% |
| HKSE | 25,952.40 | 205.96 | -0.79% |
| NASDAQ | 23,610.56 | 224.16 | -0.94% |
| Nikkei 225 | 51,497.20 | 914.14 | -1.74% |
| NZX 50 Index | 13,605.96 | 49.66 | 0.37% |
| S&P 500 | 6,812.27 | 39.70 | -0.58% |
| S&P/ASX 200 | 8,813.70 | 69.00 | -0.78% |
| SSE Composite Index | 3,960.19 | 16.33 | -0.41% |